European Society of Organ Transplantation (ESOT) Consensus Report on Downstaging, Bridging and Immunotherapy in Liver Transplantation for Hepatocellular Carcinoma.

Abstract	Liver transplantation offers the best chance of cure for most patients with non-metastatic hepatocellular carcinoma (HCC). Although not all patients with HCC are eligible for liver transplantation at diagnosis, some can be downstaged using locoregional treatments such as ablation and transarterial chemoembolization. These aforementioned treatments are being applied as bridging therapies to keep patients within transplant criteria and to avoid them from dropping out of the waiting list while awaiting a liver transplant. Moreover, immunotherapy might have great potential to support downstaging and bridging therapies. To address the contemporary status of downstaging, bridging, and immunotherapy in liver transplantation for HCC, European Society of Organ Transplantation (ESOT) convened a dedicated working group comprised of experts in the treatment of HCC to review literature and to develop guidelines pertaining to this cause that were subsequently discussed and voted during the Transplant Learning Journey (TLJ) 3.0 Consensus Conference that took place in person in Prague. The findings and recommendations of the working group on Downstaging, Bridging and Immunotherapy in Liver Transplantation for Hepatocellular Carcinoma are presented in this article.
Authors	Marco Petrus Adrianus Wilhelmus Claasen, Dimitri Sneiders, Yannick Sebastiaan Rakké, René Adam, Sherrie Bhoori, Umberto Cillo, Constantino Fondevila, Maria Reig, Gonzalo Sapisochin, Parissa Tabrizian, Christian Toso
Journal	Transplant international : official journal of the European Society for Organ Transplantation (Transpl Int) Vol. 36 Pg. 11648 ( 2023) ISSN: 1432-2277 [Electronic] Switzerland
PMID	37779513 (Publication Type: Journal Article)
Copyright	Copyright © 2023 Claasen, Sneiders, Rakké, Adam, Bhoori, Cillo, Fondevila, Reig, Sapisochin, Tabrizian and Toso.
Topics	Humans Carcinoma, Hepatocellular (surgery, pathology) Liver Neoplasms (surgery, pathology) Liver Transplantation (adverse effects) Treatment Outcome Chemoembolization, Therapeutic (adverse effects) Neoadjuvant Therapy (adverse effects) Neoplasm Staging Immunotherapy

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!